anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Coronavirus Disease 2019 (Covid19)
Conditions
Coronavirus Disease 2019 (Covid19), Hematopoietic Neoplasms
Trial Timeline
Mar 22, 2021 → Jan 1, 2023
NCT ID
NCT04951323About anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)
anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer) is a phase 3 stage product being developed by Pfizer for Coronavirus Disease 2019 (Covid19). The current trial status is unknown. This product is registered under clinical trial identifier NCT04951323. Target conditions include Coronavirus Disease 2019 (Covid19), Hematopoietic Neoplasms.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04951323 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Coronavirus Disease 2019 (Covid19)